EyesOn Strategic Growth via M&A

Strategic Expansion Through M&A: Amneal and Lilly Deploy Capital to Capture Next Growth Waves

From biosimilars scale to targeted oncology innovation, recent deals highlight how companies are using acquisition to accelerate positioning across key therapeutic and market opportunities.

Executive Highlights

•    Amneal Pharmaceuticals is acquiring Kashiv BioSciences for $750M upfront + $350M milestones, expanding into a biosimilars market projected to grow from $40B to $200B by 2035.

•    Eli Lilly continues its acquisition streak with Ajax Therapeutics (up to $2.3B), targeting next-generation oncology mechanisms.

•    Both companies are using M&A to accelerate access to differentiated capabilities rather than build internally.

•    These moves reflect a broader shift toward multi-lever strategy execution: capital allocation, portfolio focus, and speed to market.

What Happened: Targeted M&A to Accelerate Growth

Two recent transactions illustrate how companies are using M&A to reposition for long-term growth.

Amneal Pharmaceuticals announced the acquisition of Kashiv BioSciences, gaining biosimilars R&D and manufacturing capabilities across India and the U.S., along with an expanding pipeline targeting major biologic franchises.

At the same time, Eli Lilly acquired Ajax Therapeutics, securing AJ1-11095, a clinical-stage Type II JAK2 inhibitor aimed at improving outcomes in myelofibrosis.

While operating in different segments, both transactions reflect a common theme:

using acquisition to rapidly secure position in high-growth or high-value therapeutic areas.

Key Data Points: Scale vs Differentiation

Amneal / Kashiv BioSciences

•    Deal: $750M upfront + $350M milestones

•    Manufacturing capacity: 25,000L → 75,000L by 2028

•    Pipeline targets:

◦                      Amgen (Neupogen, Neulasta, Prolia, Xgeva)

◦                      Roche (Avastin)

◦                      Merck (Keytruda)

•    Launch cadence: 3–5 biosimilars per year

•    Revenue outlook:

◦                      2025: $3.02B

◦                      2030 forecast: $4.25B–$4.5B

Lilly / Ajax Therapeutics

•    Deal: up to $2.3B

•    Lead asset: AJ1-11095 (Type II JAK2 inhibitor)

•    Development: Phase 1 → rapid advancement planned

•    Differentiation:

◦                      Targets disease biology (vs symptom control)

◦                      Potential for longer-lasting efficacy and resistance management

Broader Lilly context

•    Multiple recent deals:

◦                      Ventyx ($1.2B)

◦                      Verve ($1B)

◦                      Kelonia ($3.3B)

👉 Lilly is actively deploying capital across multiple innovation platforms simultaneously

Strategic Meaning: Two Different Paths to the Same Goal

While Amneal and Lilly operate in very different segments, their strategies reflect the same core principle:

Use capital to accelerate access to growth rather than build incrementally.

Amneal: Scale, Cost Leadership, and Market Timing

Amneal’s acquisition is a scale-driven strategy focused on:

•    Capturing upcoming biologic loss of exclusivity

•    Expanding manufacturing capacity ahead of demand

•    Leveraging regulatory improvements in biosimilars

The key lever here is:
👉 Timing + scale in a cost-sensitive market

This positions Amneal to compete aggressively as:

•    Pricing pressure increases

•    Payer demand for lower-cost biologics expands

Lilly: Differentiation, Innovation, and Clinical Advantage

Lilly’s strategy is fundamentally different:

•    Focus on mechanistic differentiation

•    Targeting unmet need in resistant patient populations

•    Building a pipeline of next-generation therapies

The Ajax deal reflects:

•    A “follow-on innovation” strategy within an established class

•    A focus on improving depth and durability of response

👉 The key lever:
clinical differentiation tied to long-term market positioning

Multi-Lever Strategy in Practice

These transactions illustrate how companies are applying multiple strategic levers simultaneously:

Lever	Amneal	Lilly
Capital allocation	Scale manufacturing	Fund innovation pipeline
Portfolio focus	Biosimilars expansion	Oncology depth
Speed	Acquire capacity	Acquire clinical-stage assets
Market positioning	Cost leadership	Clinical differentiation

👉 This directly reflects the broader trend: success depends on aligning capital, portfolio, and execution—not optimizing a single dimension.

What to Watch

•    Acceleration of biosimilar launches tied to major biologic expirations

•    Pricing pressure in biosimilars markets as competition increases

•    Clinical proof-of-concept data from AJ1-11095 (expected 2026)

•    Continued acquisition activity from Lilly across therapeutic platforms

🔑 Key Takeaway

M&A is increasingly being used not just to add assets—but to rapidly align portfolio, capabilities, and timing with the next wave of market opportunity.

Further Reading from PharmaTell Studio

• Lilly / Ajax Deal

• Amneal / Kashiv Deal